Study of the treatment adherence in patients with Parkinson's disease from the community pharmacy and the Parkinson associations from the Region of Murcia

Authors

  • Mª Dolores Meseguer Illán Universidad Católica de Murcia, Facultad de Ciencias de la Salud, Departamento de Farmacia, Murcia
  • Pilar Zafrilla Rentero Universidad Católica de Murcia, Facultad de Ciencias de la Salud, Departamento de Farmacia, Murcia https://orcid.org/0000-0002-1463-7120
  • María Victoria López Federación de asociaciones de Parkinson de la Región de Murcia https://orcid.org/0000-0002-8689-7263
  • Purificación Ballester Universidad Católica de Murcia, Facultad de Ciencias de la Salud, Departamento de Farmacia, Murcia
  • Begoña Cerdá Martínez-Pujalte https://orcid.org/0000-0003-0385-1145

DOI:

https://doi.org/10.60103/phc.v24i6.779

Keywords:

Parkinson's disease; adherence; treatment; patient; quality of life; clinical pharmacy services

Abstract

Introduction: Lack of adherence to drug treatment is one of the main problems in patients with chronic diseases. A lack of adherence is related to an increase in disability and healthcare costs. The main objective of this article is to evaluate the degree of adherence to treatment in patients with Parkinson's disease. 

Method: An observational, longitudinal and prospective study has been carried out in collaboration with the Federation of Parkinson's Associations of the Region of Murcia (FEPAMUR) and collaborating pharmacies of the Region of Murcia. A patients demographic data collection procedure (sex and age) was carried out in order to characterize them. Besides, adherence to treatment was evaluated using the Morisky-Green test and the Hermes test.

Results: When studying adherence with the Morisky-Green Test, it could be seen that 64% had low adherence to treatment, 19% had medium adherence, while only 17% of the patients were highly adherent. According to the Hermes test, it was observed that 42% of the patients were adherent to treatment.

Conclusions: There is a low adherence to pharmacological treatment, according to the Hermes test and the Morisky-Green test. According to sex, we conclude that women are more adherent than men, and if we focus on the age, patients under 60 years of age are more adherent.

Downloads

Download data is not yet available.

References

Carvalho A, Barbirato D, Araujo N, Martins J.V, Sá Cavalcanti J.L, Santos T.M, Coutinho E.S, Laks J. and Deslandes A.C. Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson disease. Clin Interv Aging. 2015;10:183-91. doi: 10.2147/CIA.S68779.

Straka I, Minár M, Gazová A, Valkovic P and Kyselovic J. Clinical aspects of adherence to pharmacoteraphy in Parkinson disease: A PRISMA-compliant systematic review. Medicine (Baltimore). 2018; 97(23): e10962. DOI: 10.1097/MD.0000000000010962

García Jiménez E. Incumplimiento como causa de problema relacionado con medicamentos en el seguimiento farmacoterapéutico [Tesis Doctoral en Farmacia] Granada: Servicio de Publicación e Intercambio Científico, Universidad de Granada;2003.

World Health Organization. (2003). Adherence to long-term therapies : evidence for action. World Health Organization. Disponible en: https://apps.who.int/iris/handle/10665/42682

Fleisher J.F, Dahodwala N.A, Mayo M, Weintraub D, Chodosh J, Shea J.A. Development and validation of the Parkinson´s Disease Medication Beliefs Scale (PD-Rx). J Parkinson Dis. 2016;6(2):383-392. doi: 10.3233/JPD-150765.

Trucker C, Behoora I, Nembhard H.B, Lewis M, Sterling N.W. Machine Learning Classification of Medication Adherence in Patients with Movement Disorders Using Non-Wearable Sensors. Comput Biol Med. 2015; 66:120-34. doi: 10.1016/j.compbiomed.2015.08.012.

Martínez R, Gasca C, Sánchez A, Obeso J. Actualización en la enfermedad de Parkinson. Parkinson´s Disease: A Review. Rev. Med. Clin. Condes. 2016;27(3):363-379. doi:10.1016/j.rmclc.2016.06.010.

Casas Anguita J, Repullo Labrador J.R, Donado Campos J. La encuesta como técnica de investigación. Elaboración de cuestionarios y tratamiento estadístico de los datos (I). Aten Primaria. 2003; 31(8):527-538.

García Ferrando M. La encuesta. En: Garcia M, Ibáñez J, Alvira F. El análisis de la realidad social. Métodos y técnicas de Investigación. En: Alianza Editorial. Madrid: Alianza Universidad: 1986.

Sierra Bravo R. Técnicas de investigación social. En: Paraninfo. Madrid. 1994;240-369.

Cea D´Ancona M.A. Metodología cuantitativa. Estrategias y técnicas de investigación social. En: Síntesis sociología. Madrid. 1998:271-281.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24:67-74.

Jabary NS, Castrodeza J, Monfa JM, Sousa F, Plagaro MF, Martin A. Validación de un nuevo test para determinar el cumplimiento terapéutico en pacientes hipertensos: test Hermes. Hipertensión. Aten Primaria. 1999; 16:298-303.

Kim H, Sefcik J.S, Bradway C. Characteristics of qualitative descriptive studies: A systematic Review. Res Nurs Health. 2017;40(1):23-42. doi: 10.1002/nur.21768.

Vetter T. Fundamentals of Research Data and Variables: The Devil is in Details. Anesthesia and Analgesia. 2017;125(4):1375-1380. doi: 10.1213/ANE.0000000000002370.

García Salinero J. Análisis de datos en los estudios epidemiológicos V. Prueba de Chi cuadrado y Análisis de la varianza, Dep. Investigación FUDEN. Nure Investigación. 2006; 20. Disponible en: https://www.nureinvestigacion.es/OJS/index.php/nure/article/view/273/254

Argimon JM, Jiménez J. Métodos de investigación clínica y epidemiológica. 4ª Edición. En: Ediciones Harcourt, S.A. Editorial Elsevier. Madrid. 1999.

España. Jefatura del Estado. Ley 27/2011, de 1 de Agosto, sobre actualización, adecuación y modernización del Sistema de Seguridad Social. BOE núm 184, (Ago. 2, 2011).

Cerri S, Mus L, Blandini F. Parkinson´s Disease in Women and Men: What´s the Difference?. Review, J Parkinsons Dis. 2019; 9(3):501-515. doi: 10.3233/JPD-191683.

Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahim HA, Emre M. The effects of rasagiline on cognitive deficits in parkinso´s disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011; 26(10):1851-1858. doi: 10.1002/mds.23738.

Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo pd. Clin Neuropharmacol. 2012;35(3):121-124. doi: 10.1097/WNF.0b013e31823b1da8.

Aggarwal S, Paul G, Paul BS, Mahendru D, Goyal S. Factors affecting adherence to pharmacoteraphy in Parkinson´s disease. Ann Indian Acad Neurol. 2021; 24(6):879-884. doi: 10.4103/aian.AIAN_143_21.

Instituto Nacional de Estadística (INE). [Internet] Madrid: INE; [Consultado en Sep 2022]. Disponible en: https://www.ine.es/dyninfo/infografia/Territoriales/ capitulo.html#!tabla

Published

2022-12-15

How to Cite

Meseguer Illán, M. D., Zafrilla Rentero, P., López, M. V., Ballester, P., & Cerdá Martínez-Pujalte, B. (2022). Study of the treatment adherence in patients with Parkinson’s disease from the community pharmacy and the Parkinson associations from the Region of Murcia. Pharmaceutical Care España, 24(6), 7–17. https://doi.org/10.60103/phc.v24i6.779

Issue

Section

Originales